SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the launch of the t:lock™ Connector for its insulin pump cartridges and infusion sets. All of the infusion sets currently offered by the Company will be made available with the new t:lock Connector, produced and supplied by Unomedical a/s, a ConvaTec Group Plc company.
The t:lock Connector was designed to look and feel like the previous Luer-lock connector, while improving the customer experience of filling an infusion set with insulin. The Connector incorporates a smaller inner cavity, which reduces the amount of insulin used in the process and reduces the time required to fill the infusion set tubing.
“This launch strengthens our overall insulin delivery systems, addressing one of our customers’ most frequent requests to make the infusion set fill process more efficient,” said Kim Blickenstaff, President and CEO of Tandem Diabetes Care. “We continue to invest in ways to improve our products and deliver new technology, as part of our overall mission to provide innovative solutions to help improve the lives of people with diabetes.”
“We are excited to further our current partnership with Tandem Diabetes Care with the implementation of their optimized t:lock Connector,” said John M. Lindskog, President of ConvaTec Infusion Devices (Unomedical). “The available t:lock line of infusion sets offers a variety of solutions for their customers, and we look forward to working with Tandem to further expand their offerings in the future.”
Unomedical manufactures Tandem’s existing sets as well as many of the most popular private-labeled infusion sets of major insulin pump manufacturers under their respective brand names. The t:lock versions of Tandem’s current infusion sets will be sold under the brand names AutoSoft™, VariSoft™ and TruSteel™. Tandem will conduct a gradual rollout of its t:lock Connector to all customers and distributors beginning September 5, 2017 and anticipates fully transitioning by the end of 2017.
Information for Current Tandem Customers
No action is required by Tandem customers at this time. Tandem and its authorized distributors will work with customers to provide current Luer-lock versions of infusion sets and cartridges that are compatible with supplies they have on hand before transitioning to the t:lock Connector cartridges and infusion sets (while supplies last). Only t:lock Connector infusion sets will work with the new t:lock Connector cartridges. Infusion sets and cartridges featuring the t:lock Connector will have the same insurance coverage as current supplies.
For more information on the t:lock Connector, please visit www.tandemdiabetes.com/tlock.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements, and the t:slim G4™ Insulin Pump, the first continuous glucose monitoring-enabled pump with touchscreen simplicity. Tandem is based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2,
#tslimG4, #tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
t:slim, t:flex, and Tandem Diabetes Care are registered trademarks, and t:slim X2, t:slim G4 and t:lock are trademarks of Tandem Diabetes Care, Inc. All other trademarks are the property of their respective owners.
Forward Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding the timing of the rollout of the t:lock Connector and the Company’s expectations that the t:lock Connector will make the infusion set fill process more efficient. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, the Company may be unable to manufacture infusion sets with the t:lock connector at volumes necessary to support the needs of its existing and future customers, the anticipated rollout period may take longer than anticipated, and the Company may not ultimately be able to gain market acceptance for the t:lock Connector. In addition, the Company’s results may be impacted by the other risks identified in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.